Clinical Trial Update: A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 study of BMS-833923 (XL139), a hedgehog pathway inhibitor, in advanced or metastatic cancer. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma
• Basal Cell Nevus Syndrome

Drugs mentioned

• BMS-833923 (XL139) (BMS-833923)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hedgehog Pathway, Smoothened | Phase 1 | Status: COMPLETED